Corvus Pharmaceuticals, Inc. (CRVS) research
Corvus Pharmaceuticals, Inc.- Sector
- Healthcare
- Industry
- Biotechnology
- Last price
- $12.42
- As of
Corvus Pharmaceuticals, Inc. (CRVS): 4 institutional managers tracked by Kresmion reported non-option positions in their 2026Q2 Form 13F filings, and the most recent SEC filing on record for the company is a Form 8-K filed 2026-08-06.
As of . Source: SEC EDGAR filings for CRVS. Method and limitations.
Share the CRVS intelligence card
See CRVS live in the terminal
Track CRVS's insider trades, 13F flows, options positioning, and cross asset confluence as they update, on one live board. Free account.
Open the live CRVS terminal, freeActive signals for CRVS
- highINSTITUTIONAL_SURGE
CITADEL ADVISORS LLC added +127% to CRVS (2026Q2)
- highINSTITUTIONAL_SURGE
CITADEL ADVISORS LLC added +155% to CRVS (2026Q2)
- highINSTITUTIONAL_SURGE
D. E. Shaw & Co., Inc. added +105% to CRVS (2026Q2)
- highINSTITUTIONAL_SURGE
CITADEL ADVISORS LLC added +155% to CRVS (2026Q2)
- highINSTITUTIONAL_SURGE
CITADEL ADVISORS LLC added +127% to CRVS (2026Q2)
FREE, NO ACCOUNT
Every signal on CRVS, as it fires
You are seeing 5 of 16 signals recorded on CRVS since 2026-05-16.
The five above all landed on 2026-09-06. The other 11 were recorded on 4 other days. 12 of the 16 are institutional flow rows, which arrive in batches on filing days.
No fixed schedule: it goes out when the data has something in it. Unsubscribe anytime. We never sell your data.
Largest reported share positions in CRVS (2026Q2)
| Manager / security | Market value | % portfolio | QoQ |
|---|---|---|---|
| MILLENNIUM MANAGEMENT LLCCUSIP 221015100 · 2026Q2 | $15.7M | 0.01% | , |
| TWO SIGMA INVESTMENTS, LPCUSIP 221015100 · 2026Q2 | $11.7M | 0.01% | , |
| CITADEL ADVISORS LLCCUSIP 221015100 · 2026Q2 | $5.9M | 0.00% | , |
| D. E. Shaw & Co., Inc.CUSIP 221015100 · 2026Q2 | $2M | 0.00% | , |
Quarterly SEC Form 13F disclosures from the managers Kresmion tracks, not a complete ownership ranking. Non-option holdings only; reported put and call positions are excluded. Different securities are labeled by CUSIP. Values are reporting-period snapshots, not current position values. Filings can arrive up to 45 days after quarter-end.
Recent SEC filings, CRVS
- 8-KSEC EDGAR ↗
- 10-QSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 10-QSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
CRVS against its peers
CRVS's return on equity of -25.0% ranks in the 83rd percentile of 14 Biotechnology sub-industry peers, fiscal periods ending between 2025-12-31 and 2026-03-31.
| Metric | CRVS | Peer median | Percentile | n |
|---|---|---|---|---|
| Revenue FY | n/a | 49.8M | n/a | 9 |
| Operating margin | n/a | -200.6% | n/a | 8 |
| Net margin | n/a | -189.1% | n/a | 8 |
| Return on equity | -25.0% | -66.0% | 83 | 14 |
Peers (17): MLTX, SVRA, JBIO, KURA, ABUS, JANX, SLDB, CADL, DSGN, GLUE, SANA, AVTX, MNKD, SGP, REPL, MGTX, LXRX. Left out: ATTO (no annual filing), OBX (no annual filing), HELP (period gap), APMD (no annual filing), ANL (period gap), SLBT (no annual filing), ODTX (no annual filing), SPTX (no annual filing). Fiscal periods ending between 2025-12-31 and 2026-03-31. Every figure is one full fiscal year read from one annual filing (CRVS: 10-K), reported in USD. Nothing is trailing twelve months and nothing is converted between currencies. Source: SEC EDGAR XBRL company facts (public domain); prices from Kresmion's daily equity market-data snapshot. Open the full comparison.
Related tickers
See more CRVS signals as they fire
Kresmion publishes filings, 13F flows, on-chain whale activity, and cross-asset signals in real time. Open a live board scoped to CRVSand get the insider, 13F, options, and confluence read in one view.